Physician profile
Datar Singh
NPI 1164483038
$15,088.30
in general payments reported to CMS, 2019-2025
38 companies · $9,460 in 2025
The $9,460 reported for 2025 was more than what 99% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $532 · 2020: $401 · 2021: $618 · 2022: $2,330 · 2023: $904 · 2024: $844 · 2025: $9,460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $6,000 · Food and Beverage: $3,170 · Travel and Lodging: $1,688 · Debt Forgiveness: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $6,000.00 |
| Food and Beverage | $3,169.58 |
| Travel and Lodging | $1,688.13 |
| Debt Forgiveness | $350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,828.04 | 2025 | |
| Boston Scientific Corporation | $2,094.52 | 2022-2025 | General - Therapies |
| Abbvie INC. | $660.75 | 2019-2024 | Lo Loestrin Fe |
| Novo Nordisk INC | $600.76 | 2023-2025 | Wegovy, Saxenda |
| Pfizer INC. | $386.24 | 2019-2025 | |
| Olympus America INC. | $350.00 | 2025 | |
| Mayne Pharma Commercial LLC | $330.57 | 2021-2025 | |
| Lupin INC. | $299.64 | 2019-2021 | |
| Coopersurgical, INC. | $278.03 | 2019-2025 | Endosee |
| Currax Pharmaceuticals LLC | $227.84 | 2021-2024 | Contrave, Onzetra Xsail, Nexlizet |
| Organon LLC | $189.55 | 2021-2025 | Nexplanon |
| Astellas Pharma US INC | $175.08 | 2022-2025 | Veozah, Myrbetriq |
| Edwards Lifesciences Corporation | $170.96 | 2024 | |
| Exeltis, USA INC. | $165.82 | 2021-2024 | Slynd |
| Lilly USA, LLC | $145.26 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $130.46 | 2023-2025 | Myfembree |
| Amgen INC. | $124.47 | 2023 | Evenity |
| Exact Sciences Corporation | $110.27 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $85.31 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $79.89 | 2019-2021 | |
| Millicent US INC | $75.92 | 2025 | Femlyv, Intrarosa |
| Indivior INC. | $67.18 | 2019-2020 | |
| Allergan, INC. | $62.00 | 2019-2021 | |
| Shield Therapeutics INC | $59.13 | 2023-2024 | Accrufer |
| Sage Therapeutics, LLC | $47.60 | 2025 | Zurzuvae |
| Coloplast Corp | $42.58 | 2021 | |
| Hologic Sales and Service, LLC | $36.38 | 2023-2025 | Aptima, Thinprep 2000 Processor, Acessa Provu System |
| Mylan Pharmaceuticals INC. | $32.90 | 2021-2022 | |
| Arjo INC. | $31.54 | 2025 | |
| Myovant Sciences INC. | $29.81 | 2022 | |
| Avion Pharmaceuticals | $28.71 | 2021-2022 | |
| Axonics, INC. | $28.68 | 2023 | Bulkamid, Axonics |
| Agile Therapeutics, INC. | $24.05 | 2021 | |
| Evofem Biosciences, INC. | $22.31 | 2021 | |
| Vivus LLC | $19.45 | 2020 | |
| Amag Pharmaceuticals, INC. | $17.07 | 2019 | |
| Ethicon US, LLC | $15.81 | 2021 | |
| Orexo US, INC. | $13.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Datar Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.